- You can view the full Allergan Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Allergan ( AGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.6%. By the end of trading, Allergan rose $0.90 (1.0%) to $88.83 on light volume. Throughout the day, 1,311,512 shares of Allergan exchanged hands as compared to its average daily volume of 2,721,600 shares. The stock ranged in a price between $87.64-$89.20 after having opened the day at $87.64 as compared to the previous trading day's close of $87.93. Other companies within the Health Care sector that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 13.6%, Bovie Medical Corporation ( BVX), up 11.9%, Arrhythmia Research Technology ( HRT), up 11.7% and Genvec ( GNVC), up 11.1%. Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $26.2 billion and is part of the drugs industry. Shares are down 4.1% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 11 rate it a hold. TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
